Bwx Technologies Inc - BWXT STOCK NEWS

BWX Technologies, Inc. (NYSE: BWXT), parent company of Nuclear Fuel Services (NFS), has announced a $100,000 donation to the Unicoi County United Way to support recovery efforts in Erwin, Tennessee following Hurricane Helene. The contribution will aid emergency response teams in providing essential supplies, medical aid, shelter, and long-term recovery services.

BWXT CEO Rex Geveden expressed solidarity with the Erwin community, where NFS has been operating since 1957. The company is also facilitating employee donations and organizing volunteer efforts to assist in the recovery process. NFS, a part of BWXT's Nuclear Operations Group, processes highly enriched uranium for naval nuclear reactors and provides uranium downblending services.

BWX Technologies (NYSE: BWXT) has been awarded a contract by the National Nuclear Security Administration (NNSA) to conduct a yearlong engineering study for the Domestic Uranium Enrichment Centrifuge Experiment (DUECE) program. The study aims to evaluate options for deploying a centrifuge pilot plant to establish domestic uranium enrichment capabilities for national security purposes.

The contract, awarded to BWXT subsidiary Nuclear Fuel Services, Inc., represents the next phase of the DUECE program. The objective is to inform the acquisition approach for a pilot plant that will demonstrate centrifuge performance, reliability, and life-cycle costs for the NNSA. Fluor will serve as the engineering, procurement, and construction service provider for this activity.

This initiative aligns with BWXT's strategy to expand its role in the national security nuclear fuel cycle, leveraging its unique nuclear operations infrastructure and NRC Category 1 uranium handling and processing licenses.

BWX Technologies, Inc. (NYSE: BWXT) has appointed Vittorio Puppo as president of BWXT Medical , effective August 12, 2024. Puppo brings over 30 years of experience in imaging, nuclear medicine, radiation therapy, and biotech. He previously served as COO of Radiopharm Theranostics and held various positions at Bracco, including chief marketing and strategy officer.

Puppo succeeds Jonathan Cirtain, who will transition back to his role as BWXT's chief development officer. BWXT Medical manufactures custom radiopharmaceuticals, radiotherapies, and medical isotopes in Ottawa and at TRIUMF's commercial cyclotron facility. The company aims to deliver high-quality nuclear medical products and solutions to improve patient outcomes worldwide.

BWX Technologies (NYSE: BWXT) reported strong second quarter 2024 results, with revenues of $681.5 million, net income of $73.0 million, and adjusted EBITDA of $126.2 million. The company's diluted GAAP EPS was $0.79, while non-GAAP EPS reached $0.82. BWXT revised its 2024 non-GAAP EPS guidance to $3.10-$3.20. The company saw solid organic growth across its business lines, with the Government Operations segment revenue increasing by 10% and Commercial Operations by 17%. BWXT also highlighted recent positive developments in nuclear markets, including the passage of the ADVANCE Act and support for small modular reactor development, which are expected to drive new opportunities for the company.

BWXT Medical and NorthStar Medical Radioisotopes have signed a Master Services Agreement (MSA) to collaborate on the production of actinium-225 (Ac-225), a critical medical isotope used in cancer treatments. The multi-year agreement focuses on processing and purifying radium-226, with potential for target design projects and backup supply opportunities.

This collaboration aims to streamline production processes, enhance safety protocols, and innovate new methods of isotope generation. BWXT Medical recently submitted a Drug Master File (DMF) for Actinium-225 API to the FDA, enabling clinical investigators and pharmaceutical companies to reference it in their regulatory submissions. The partnership is expected to accelerate radium-226 target design and fabrication efforts, expanding Ac-225 production capabilities.

BWX Technologies (NYSE: BWXT) announced that it will release its second quarter 2024 financial results on Monday, August 5, 2024, after the market closes. The company will hold a conference call to discuss these results at 5:00 p.m. EDT. Investors can access the call and supporting presentation through BWXT's investor relations website. The dial-in numbers for participants are 1-888-596-4144 (U.S.) and 1-646-968-2525 (International), with the conference ID 7880317. A replay of the call will be available on the BWXT website for a period. BWX Technologies is a U.S.-based Fortune 1000 company specializing in nuclear solutions for various sectors, including global security, clean energy, and nuclear medicine, employing approximately 7,800 individuals across multiple international sites.

BWX Technologies (NYSE: BWXT) announced it has secured the second phase of a contract from the Wyoming Energy Authority. This contract aims to assess the deployment of small-scale nuclear reactors in Wyoming as part of a resilient energy strategy. Phase one focused on defining nuclear application requirements and identifying Wyoming's supply chain capabilities. The $20 million cost-share program's phase two will involve conceptual design, regulatory planning, and demonstrating manufacturing capabilities. Completion is expected by Q3 2025. The initiative leverages the U.S. Department of Energy's Advanced Reactor Demonstration Program achievements and involves collaboration with Idaho National Laboratory.

BWX Technologies (BWXT) announced a $30 billion contract from the U.S. Department of Energy's National Nuclear Security Administration (DOE/NNSA) for managing and operating the Pantex Plant. The initial contract term is five years, with the possibility of three additional five-year options, extending to 20 years if fully exercised. The contract was awarded to PanTeXas Deterrence (PXD), a joint venture led by a BWXT subsidiary, including Fluor, SOC, A Day & Zimmermann Company, and The Texas A&M University System. Pantex is important for maintaining the U.S. nuclear weapons stockpile, supporting life extension programs, and other nuclear operations. The transition period will last four months, starting on an undetermined date.

BWXT Medical has submitted a Drug Master File (DMF) to the FDA for its No Carrier Added (n.c.a.) Actinium-225 (Ac-225) Active Pharmaceutical Ingredient. Ac-225 is an alpha-emitting isotope important for targeted alpha therapies (TATs) that selectively kill cancer cells. The DMF submission highlights BWXT's commitment to quality and regulatory standards, ensuring safety and efficacy. The isotope is produced via high-energy proton spallation of thorium targets, a method developed in collaboration with TRIUMF to yield high purity Ac-225. This filing supports clinical and pharmaceutical developments, marking a significant milestone for BWXT Medical.